不符合ACR TI-RADS细针穿刺标准的恶性甲状腺结节分析
本研究回顾性分析3422个甲状腺结节,按ACR TI-RADS分为细针穿刺组、超声随访组和无进一步评估组,评估不符合穿刺标准的恶性结节特征。352个恶性结节中,40个被建议无进一步评估,其中16个≥1 cm;
要点
- ACR TI-RADS建议无进一步评估的恶性结节多数<1 cm或会接受超声随访。
- 40个恶性结节被建议无进一步评估,其中16个≥1 cm。
- 降低TR3随访阈值至1.0 cm可额外检出7个恶性结节,但增加118个良性结节随访。
核心结论
- 使用ACR TI-RADS,大多数不会接受穿刺的恶性结节会接受超声随访、小于1 cm或两者兼有。
- 调整大小阈值以减少≥1 cm的漏诊恶性结节会导致接受随访的良性结节数量大幅增加。
研究设计与样本
- 回顾性研究,共纳入3422个甲状腺结节,均有明确细胞学诊断、明确组织学诊断或两者兼有,以及诊断性超声检查。
- 所有结节按ACR TI-RADS分类,并根据推荐分为三组:细针穿刺组(第1组)、超声随访组(第2组)、无进一步评估组(第3组)。
关键影像表现/征象
- 352个恶性结节中,240个被分入第1组,72个分入第2组,40个分入第3组。
- 第3组40个恶性结节中16个≥1 cm,根据ACR TI-RADS描述的超声特征分类为TR1至TR5五个风险级别,其中1个为TR1、8个为TR2、7个为TR3。
诊断标准与关键数值
- ACR TI-RADS推荐:TR2结节无随访;TR3结节≥1.5 cm建议超声随访。
- 若将TR2结节无随访改为≥2.5 cm随访,额外7个恶性结节和316个良性结节将接受随访推荐。
- 若将TR3结节超声随访的大小阈值从1.5 cm降至1.0 cm,额外7个恶性结节和118个良性结节将接受随访推荐。
临床应用与阅片要点
- 按ACR TI-RADS阅片时,被建议无进一步评估的恶性结节多数<1 cm或会接受超声随访。
- 调整TR2和TR3的大小阈值可减少≥1 cm的漏诊恶性结节,但会大幅增加良性结节的随访数量。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE. Compared with other guidelines, the American College of Radiology (ACR) Thyroid Imaging Reporting and Data System (TI-RADS) has decreased the number of nodules for which fine-needle aspiration is recommended. The purpose of this study was to evaluate the characteristics of malignant nodules that would not be biopsied when the ACR TI-RADS recommendations are followed. MATERIALS AND METHODS. We retrospectively reviewed a total of 3422 thyroid nodules for which a definitive cytologic diagnosis, a definitive histologic diagnosis, or both diagnoses as well as diagnostic ultrasound (US) examinations were available. All nodules were categorized using the ACR TI-RADS, and they were divided into three groups according to the recommendation received: fine-needle aspiration (group 1), follow-up US examination (group 2), or no further evaluation (group 3). RESULTS. Of the 3422 nodules, 352 were malignant. Of these, 240 nodules were assigned to group 1, whereas 72 were assigned to group 2 and 40 were included in group 3. Sixteen of the 40 malignant nodules in group 3 were 1 cm or larger, and, on the basis of analysis of the sonographic features described in the ACR TI-RADS, these nodules were classified as having one of five ACR TI-RADS risk levels (TR1-TR5), with one nodule classified as a TR1 nodule, eight as TR2 nodules, and seven as TR3 nodules. If the current recommendation of no follow-up for TR2 nodules was changed to follow-up for nodules 2.5 cm or larger, seven additional malignant nodules and 316 additional benign nodules would receive a recommendation for follow-up. If the current size threshold (1.5 cm) used to recommend US follow-up for TR3 nodules was decreased to 1.0 cm, seven additional malignant nodules and 118 additional benign nodules would receive a recommendation for follow-up. CONCLUSION. With use of the ACR TI-RADS, most malignant nodules that would not be biopsied would undergo US follow-up, would be smaller than 1 cm, or would both undergo US follow-up and be smaller than 1 cm. Adjusting size thresholds to decrease the number of missed malignant nodules that are 1 cm or larger would result in a substantial increase in the number of benign nodules undergoing follow-up.
引用
- Middleton WD, Teefey SA, Tessler FN, et al. Analysis of Malignant Thyroid Nodules That Do Not Meet ACR TI-RADS Criteria for Fine-Needle Aspiration. AJR Am J Roentgenol. 2020. PMID: 32603228. doi:10.2214/AJR.20.23123
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。